J Korean Soc Biol Psychiatry.  1997 Jun;4(1):132-135.

Psychosis in Parkinson

• Koh SB
• Park KW
• Lee DH

Abstract

Current treatment strategies for levodopa-induced psychosis in advanced Parkinson's disease have had limited success. Reduction or discontinuation of levodopa and coadministration with dopamine-blocking neuroleptics may attenuate the psychotic symptoms, but these strategies are associated with worsening of parkinsonian symptoms. Administration of 5-HT3 receptor antagonist ; ondansetron, a newer strategy to attenuate psychosis of Parkinson' disease without motor deterioration was introduced. A 41-year-old young-onset male, who was diagnosed as Parkinson's disease 7 years ago, was treated with levodopa therapy, and had levodopa-induced psychosis(delusion, hallucination, paranoid, insomnia). After trial of ondansetron, he showed improvement in the Brief Psychiatric Rating Scale(from 21 points to 9 points) in spite of increasing the dosage of levodopa. With ondansetron, we could increase the dosage of levodopa without psychotic complications(esp, hallucination), and he showed improvement in the motor fluctuation.

MeSH Terms

Adult
Antipsychotic Agents
Hallucinations
Humans
Levodopa
Male
Ondansetron
Parkinson Disease
Psychotic Disorders*
Receptors, Serotonin, 5-HT3
Antipsychotic Agents
Levodopa
Ondansetron
Receptors, Serotonin, 5-HT3